Cardiovascular disease remains the leading cause of mortality worldwide. Semaglutide, a GLP-1 receptor agonist, has shown cardiovascular benefits, but its safety profile, including risks of various adverse events, in adults with established atherosclerotic cardiovascular disease (ASCVD) requires systematic evalua...
K. Keswani, M. Reddy, A. Aslam et al.· European Heart Journal· 0 citations
Acute heart failure (HF) patients are at high risk, especially in the first three months following discharge, when rehospitalizations are 30% common and mortality can be close to 10%. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential for treating heart failure, their benefit when initiated...
N. Shafi, F. Khalid, M. Elshabrawi et al.· European Heart Journal· 0 citations
Transradial access has revolutionized interventional cardiology by reducing vascular complications compared to femoral approaches. However, as novel techniques emerge, comprehensive quantitative synthesis comparing these methodologies remains limited, creating uncertainty regarding the optimal procedural strategy...
K. Keswani, H. Saqib, T. Khan et al.· European Heart Journal· 0 citations
BACKGROUND
Femoral vascular access is integral to diagnostic and therapeutic electrophysiology (EP) procedures but is associated with bleeding and access-site complications. Manual compression and figure-of-eight sutures remain widely used for hemostasis; however, they are resource intensive and delay ambulation. Vascu...
H. Saqib, M. Elshabrawi, Arpitha Sirichandana Baggu et al.· Pacing and clinical electrop...· 0 citations
Atrial fibrillation (AF) is highly prevalent in heart failure (HF) and is linked to increased mortality and hospitalization in both preserved (HFpEF) and reduced ejection fraction (HFrEF). Catheter ablation (CA) has emerged as an effective rhythm-control strategy beyond medical therapy (MT), but phenotype-specifi...
Faizan Ahmed, A. Zulfiqar, M. Elshabrawi et al.· BMC Cardiovascular Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.